Austin, Texas-based Acessa markets the Acessa ProVu fully integrated laparoscopic system for combining radiofrequency ablation with intra-abdominal ultrasound visualization and guidance mapping for treating women with symptomatic, benign uterine fibroids.
Marlborough, Mass.-based Hologic said in a news release that the Acessa ProVu system will complement its market-leading MyoSure products designed for the hysteroscopic removal of fibroids found in the uterine cavity.
The deal includes $80 million in cash, plus additional contingent payments based on future revenue growth, according to the release. Hologic estimates that Acessa Health will generate approximately $13 million in revenue for fiscal 2021, producing a slightly dilutive impact on Hologic’s non-Gaap earnings per share for the year, then a break-even in 2022, followed by an accretive effect thereafter.
Acessa Health co-founder and CEO Kim Rodriguez said in the release that the company believes that, under Hologic’s leadership and with its commercial presence, the Acessa ProVu system can rapidly become the standard of care.
“Acquiring Acessa Health strengthens our leadership position in the GYN surgical space and broadens our fibroid treatment portfolio with a highly complementary new product,” Hologic GYN surgical solutions division president Essex Mitchell said in the release. “Together with the Acessa team, we can leverage our core women’s health expertise, commercial infrastructure and physician relationships to accelerate our growth strategy and offer superior technology that translates into better clinical outcomes for women.”